Zymeworks Bc Inc.

Zymeworks Inc.

Rupert H Davies

James R Rich

Stuart Daniel Barnscher

Gerald J Rowse

Kevin Hamblett

Vincent K C Fung

Dunja Urosev

Michael G Brant

Raffaele Colombo

Danny Chui

Samuel Oliver Lawn

Sukhbir Singh Kang

Ada G H Young

Peter Wing Yiu Chan

Samir Das

Brandon Clavette

Andrea Hernandez Rojas

Duncan Browman

Robert William Gene

Manuel Michel Auguste Lasalle

Mark Edmund Petersen

Antibody-drug conjugates (ADCs) comprising an antibody construct that binds specifically binds human folate receptor alpha (FRα) (an anti-FRα antibody construct) conjugated to a camptothecin analogue of Formula (I). The ADCs are useful as therapeutics, in particular in the treatment of cancer.

Antibody-drug conjugates targeting folate receptor alpha and methods of use

Anti-HER2 biparatopic antibody-drug conjugates (ADCs) in which the drug is an auristatin analogue and is conjugated to the antibody at a low average drug-to-antibody ratio (DAR), and methods of using the ADCs in the treatment of a HER2-expressing cancer. The low average DAR (<3.9) ADCs as described herein have improved tolerability and decreased toxicity as compared to a corresponding ADC having a DAR ≥3.9 when administered at the same toxin dose.

Anti-HER2 biparatopic antibody-drug conjugates and methods of use

Anti-HER2 biparatopic antibody-drug conjugates (ADCs) in which the drug is an auristatin analogue and is conjugated to the antibody at a low average drug-to-antibody ratio (DAR), and methods of using the ADCs in the treatment of a HER2-expressing cancer. The low average DAR (&#x3c;3.9) ADCs as described herein have improved tolerability and decreased toxicity as compared to a corresponding ADC having a DAR&#x2265;3.9 when administered at the same toxin dose.

Growing community of inventors

Seattle, WA, United States of America

Rupert H Davies